This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...

The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity.

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Study Rundown: Studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of various forms of dementia, including vascular dementia and Alzheimer’s disease.

1. In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...